Table 3.

Courses of treatment.

EGPA Patients with IVIG, n = 22EGPA Patients without IVIG, n = 24p
PSL as initial dose, mg/kg0.96 ± 0.20.8 ± 0.2NS
Patients given steroid pulse (%)68.254.2NS*
Patients taking immunosuppressant (%)95.579.2NS*
Median time from onset to initial IVIG treatment, mo (range)3.5 (1.0–216.0)
IVIG, no. courses, mean ± SD2.6 ± 2.10p < 0.01
Mean time from first IVIG to last treatment, mo9.2 ± 10.0
PSL at 2 yrs after last IVIG or about 38 mo from onset, mg5.5 ± 2.47.7 ± 2.9p < 0.01
  • Values of p < 0.05 considered statistically significant.

  • 2-way ANOVA with repeated measures among 2 groups.

  • * Chi-square testing revealed no significant differences in the frequencies of 2 groups. EGPA: eosinophilic granulomatosis with polyangiitis; NS: not significant; PSL: prednisolone; CYC: cyclophosphamide; AZA: azathioprine; CSA: cyclosporine; IVIG: intravenous immunoglobulin.